Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Turk J Med Sci
; 51(4): 1727-1732, 2021 08 30.
Article
in En
| MEDLINE
| ID: mdl-33315355
ABSTRACT
Background/aim:
The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with pancreatic cancer. Materials andmethods:
Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary measures.Results:
There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival was 18.1 months (7.528.7) in the folfirinox group as compared with 9.7 months (6.513) in the gemcitabine-cisplatin group (p = 0.009). Median progression-free survival was 16.2 months (923.4) in the folfirinox group and 6.9 months (6.17.6) in the gemcitabine- cisplatin group (p = 0.001).Conclusion:
Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Leucovorin
/
Cisplatin
/
Deoxycytidine
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2021
Type:
Article